Click for Hawker Click for HondaJet Click for Piper Click for Boeing Click for Bombardier

News: Embraer Phenom 300MD Certified By FAA; EASA

Thread Status:
Not open for further replies.
  1. Phenom 300MD Certified By FAA; EASA
    Embraer has announced that its Medivac variant of the Phenom 300 has been Supplemental type certified (STC) by the U.S-based Federal Aviation Administration (FAA) as well as the European Aviation Safety Agency (EASA). The STC was performed at Embraer Service Center in Fort Lauderdale, Florida, and will be operated by the launch customer, on-demand charter operator Grandview Aviation. Marsha Woelber, Vice-President of Worldwide Executive Jets Customer Support & Aftermarket Sales, Embraer Service & Support commented: "We are pleased to announce the certification of the Phenom 300MED by the FAA and EASA. The Medevac solution provides superior value, benefiting from a market-leading product such as the Phenom 300 series, combining its unique capabilities with a fully-comprehensive medical solution."
  2. The Phenom 300MED aeromedical interior was specified by Embraer and developed and certified by engineering services provider umlaut, part of Accenture, utilizing Aerolite equipment. Aerolite developed the Intensive Care Unit (ICU) specifically for the Phenom 300MED. As per the certification requirements, umlaut conducted an evacuation test to confirm two fully disabled patients could be evacuated. Embraer and umlaut developed a comprehensive set of configuration alternatives for the Phenom 300MED. These configuration alternatives include either one or two stretchers, the ability to carry an incubator, and additional medical equipment. The aircraft also features hospital-grade trim and finishing also with the ability to be transformed back to an executive cabin in as little as 5 hours.

    For more information:

    Embraer
    Avenida Brigadeiro Faria Lima, 2170
    São Paulo, São José dos Campos
    12227-901
    Brazil
    www.embraerexecutivejets.com

    ***​
Thread Status:
Not open for further replies.